Sorry, but you need a new version of this browser to see this web

Update Internet Explorer


Since its beginnings in the field of Oncology, Eisai continues to increase its commitment to this disease through research and clinical development with approved treatments for cancer and palliative therapies and in the improvement of manufacturing capabilities.

Currently, Eisai is exploring several compounds with clinical studies enrolling in breast cancer, soft tissue sarcoma – liposarcoma subtype, differentiated thyroid carcinoma, renal cell carcinoma, hepatocellular carcinoma and a variety of other cancers and conditions. Eisai has a diverse in-house pipeline of oncology compounds in development and several more about to begin clinical trials for safety and efficacy evaluation.


Thank you for browsing the Eisai website.
You are about to visit an external website.
(A new browsing window will be opened)

Obrigado por navegar no site da Eisai.
VocĂȘ estĂĄ prestes a visitar um site externo.
(Uma nova janela de navegação serå aberta)